Hologenomix

Finding cancer improves your survival odds

Pancreatic cancer, for example: 3 in 100 alive after five years if found late, 44 if found early.1

Scroll ↓

Tumours shed DNA into the blood

Reading those fragments tells you about the tumour without a biopsy. This is the basis of liquid biopsies.

One tube of blood is often too little

It holds about 6,000 genome copies, and some small cancers shed less than 1 tumour copy in 10,000.2 We can't take a cup of blood.

What if we just had more material?

Urine carries cell-free DNA, tumour DNA included

The kidneys filter the blood and pass short DNA fragments into the urine.3

Accessible, non-invasive, larger volumes.

A cup of urine holds 50× more cell-free DNA than a tube of blood

300 mL against 4 mL.4 At 1 tumour copy in 10,000, the tube expects 0.6 copies. The cup, 30.

We break the extraction wall

A whole cup goes in. Pure, concentrated cell-free DNA comes out, ready for any test.

A 6% chance becomes 89% or more

100%0%1 in 1k1 in 10k1 in 100k1 in 1M1 in 10Mrarer tumour DNA →Hologenomix, 300 mLBlood

With enough volume, urine could contain the needed relevant tumor molecules consistently5

Shown in bladder cancer. Next: pancreatic and prostate cancer

PRECIS-BC, our running trial with Radboudumc, asks whether a urine test can spare the bladder. About the trial ↗

First pancreatic data: Q2 2027.

Liquid biopsy is growing. There is much more to reach

LIQUID BIOPSY TODAYA URINE KIT AT HOME354k596k+68%in a yearQ3 2025Q3 2026cancer tests a quarter, four leading tests analysts expect 11 to 14% a year12.9%23.6%1.8×participationinvited tothe clinickit mailedhomescreening participation, French trial of 13,061 women, 2025

Testing grew 68% in a year.6 In a French screening trial, a urine kit mailed home nearly doubled participation.7 Why now →

We move fast

A trial running, a patent-pending device.

The Hologenomix team at work in the lab

Team

In Delft, on the Biotech Campus.

Eric van der ToornCo-founder, CEOBioinformatician and AI researcher
TU DelftKTH Royal Institute of Technology
David Calderón FrancoCo-founder, CTOExpert in cfDNA isolation
TU DelftTechnical University of Denmarkfgen
Thomas AbeelCo-founder, CSO. Associate professorAI bioinformatician
MITTU DelftBroad Institute of MIT and Harvard
Harshitha HanjiBusiness developmentBiotech partnerships and grant funding
TU Delft
Gonçalo MacedoResearch scientistQuality and regulatory
TU DelftUtrecht UniversityMSD

Advisors

Each has taken a life-science company to a sale.

Prof. Jack SchalkenUrology professor. Co-founded NovioGendix, sold to MDxHealth
Radboudumc
Joris SchuurmansCEO SkylineDx. Sold Cergentis in 2022. Before: Biocartis, MyCartis
SkylineDx
Jan Groen, PhDChaired Vesica Health to its 2026 sale. Ex-CEO MDxHealth
Vesica HealthCelLBxHealthMDxHealth

Supported by

Health HollandProvincie Zuid-Holland, MIT feasibility studyKansen voor WestCo-funded by the European UnionUNIIQGraduate VenturesPlanet B.io

Health Holland funds the PRECIS-BC trial (TKI-LSH SME Call 2025). Provincie Zuid-Holland: MIT feasibility study. Kansen voor West is co-funded by the European Union (EFRO).

We are raising soon. Let's talk

More molecules, better tests.

[email protected]

Everything else: [email protected] · Projects and trials: [email protected]

Hologenomix B.V. · Planet B.io, Biotech Campus Delft

Notes and sources

  1. Five-year survival for pancreatic cancer: 44% if localised, 3% if it has spread (SEER). US deaths 2026: American Cancer Society. ↩
  2. Dying tumour cells release short fragments of DNA into the blood; reading them is a liquid biopsy. They thin out in five litres of blood, and a test reads one tube: a median 6,000 genome copies per blood sample in 194 patients (Zviran et al., Nature Medicine 2020). At one tumour copy in a million, the tube expects 0.006 copies of any one tumour mutation, so usually zero. “If no physical fragment that supports a targeted [mutation] is present in the sample, even ideal ultra-deep targeted sequencing will fail to discover a signal.” ↩
  3. Short DNA fragments from the blood cross the kidney into the urine (transrenal DNA): first shown with donor and fetal DNA in urine (Botezatu et al., Clinical Chemistry 2000); urine holds small, 150–250 nucleotide DNA from the circulation (Su et al., Journal of Molecular Diagnostics 2004); methylation maps the tissues it comes from (Cheng et al., Clinical Biochemistry 2017). Review: trans-renal cell-free tumour DNA for urine liquid biopsy (Frontiers in Genetics 2022). ↩
  4. Measured in healthy donors: 250–1,000 ng DNA per 100 mL of urine, rising in step with volume up to 160 mL. A morning void is ~300 mL (our device takes 100–500 mL). 3.3 pg per genome copy, so ~300,000 copies per void against a median 6,000 in a blood draw: about 50×. Counted from DNA mass; the usable human share is part of what we measure first. At 1 tumour copy in 10,000 that is 0.6 expected copies in the blood draw and about 30 in the void. ↩
  5. At 1 tumour copy in 100,000: blood 6%, a whole void 89% to ~100%. At 1 in a million: blood 0.6%, a whole void 20–59%. Urine also carries DNA from the kidneys and bladder, so its tumour share may be lower than blood's. At a tenth of blood's share (the band's lower edge), the cup still gives 20–59% against blood's 6% at 1 in 100,000. For pancreatic cancer, that share is the first thing we measure. Poisson sampling from the copy numbers in note 4. ↩
  6. Cancer liquid-biopsy tests reported for Q3 2026 against Q3 2025: Natera oncology 339,500 (from 211,000), Guardant Health oncology 117,000 (+58%), Guardant Shield 83,000 (from 24,000), GRAIL Galleri more than 56,000 (+24%). Together about 596,000 against about 354,000, +68% (company results, November 2026; the 2025 counts for Guardant oncology and Galleri are derived from the stated growth). Market forecasts: 11.5% to 14.1% a year (Grand View Research, MarketsandMarkets, Precedence Research, BCC Research; Fortune Business Insights says 28.6%). ↩
  7. CapU4 randomised trial, France: of 13,061 women who had not responded to a cervical screening invitation, 23.6% took part when a urine self-sampling kit was mailed to them, against 12.9% with an invitation to see a physician (Lefeuvre et al., Cancer Epidemiology, Biomarkers & Prevention 2025). This is HPV screening on urine, not a liquid-biopsy test, and about half of the women who responded went to a physician instead of using the kit. ↩